Evolution of the Average Target: Repligen Corporation

Evolution of the Target Price: Repligen Corporation

Changes in Analyst Recommendations: Repligen Corporation

d41395b6be086c333190753a.F4hRKSHQHeVhhCrE1TTrT_YQFQyM3wR7gnIZhIOWayc.ZNk9cEqHVodYwU_0lmyFApJiV0jVp00D0zcqsufDIWJtxBxZd4l-1yDvRQ~5e39be2261dcaf30274b0ef2efab00ce
05-15 Repligen Likely to Benefit From Diverse Growth Factors, RBC Says MT
04-17 Rothschild & Co Redburn Initiates Repligen at Buy With $160 Price Target MT
02-25 UBS Adjusts Price Target on Repligen to $195 From $200, Maintains Buy Rating MT
01-16 UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating MT
01/10/25 HSBC Initiates Repligen at Buy With $150 Price Target MT
22/09/25 Repligen Shares Rise After Upgrade From Evercore ISI MT
22/09/25 Evercore ISI Upgrades Repligen to Outperform From In Line, Price Target is $155 MT
03/09/25 RBC Lifts Price Target on Repligen to $205 From $204, Keeps Outperform Rating MT
30/07/25 RBC Raises Price Target on Repligen to $204 From $193, Keeps Outperform Rating MT
29/07/25 Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance RE
01/07/25 RBC Lifts Price Target on Repligen to $193 From $191, Keeps Outperform Rating MT
24/06/25 Barclays Initiates Repligen at Overweight With $150 Price Target MT
30/04/25 RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating MT
29/04/25 Wolfe Research Upgrades Repligen to Outperform From Peerperform MT
08/04/25 RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating MT
18/03/25 Evercore ISI Initiates Repligen at In Line With $155 Price Target MT
21/02/25 RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating MT
21/02/25 Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating MT
10/02/25 TD Cowen Initiates Repligen at Buy With $200 Price Target MT
04/02/25 RBC Trims Price Target on Repligen to $203 From $207, Keeps Outperform Rating MT
09/12/24 RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating MT
14/11/24 Wolfe Research Initiates Repligen at Peer Perform MT
13/11/24 UBS Adjusts Price Target on Repligen to $190 From $185, Keeps Buy Rating MT
13/09/24 RBC Raises Price Target on Repligen to $205 From $190, Keeps Outperform Rating MT
31/07/24 UBS Lowers Repligen's Price Target to $185 From $205, Buy Rating Maintained MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+28.54%
+25.71%
+20.81%
+24.62%
+17.73%
+14.54%
+29.13%
+21.81%
+1.16%
+20.45%
Average +20.45%
Weighted average by Cap. +21.63%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
137.00USD
Average target price
176.11USD
Spread / Average Target
+28.54%
High Price Target
220.00USD
Spread / Highest target
+60.58%
Low Price Target
142.00USD
Spread / Lowest Target
+3.65%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Rothschild & Co Redburn
UBS
HSBC
Evercore ISI
RBC Capital Markets
Barclays
Wolfe Research
Deutsche Bank Securities
TD Cowen
Guggenheim
Benchmark Company
KeyBanc Capital Markets
Craig-Hallum
JPMorgan Chase
Stephens Inc.
Wells Fargo Securities
Stifel Nicolaus
SVB Securities LLC
SVB Leerink
Exane BNP Paribas
William O'Neil & Co
HC Wainwright
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
137.00USD
Average target price
176.11USD
Spread / Average Target
+28.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RGEN Stock
  4. Consensus Repligen Corporation